Small‐molecule inhibition of MuRF1 attenuates skeletal muscle atrophy and dysfunction in cardiac cachexia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Muscle ring finger 1 (MuRF1) is a muscle‐specific ubiquitin E3 ligase activated during clinical conditions associated with skeletal muscle wasting. Yet, there remains a paucity of therapeutic interventions that directly inhibit MuRF1 function, particularly in vivo . The current study, therefore, developed a novel compound targeting the central coiled coil domain of MuRF1 to inhibit muscle wasting in cardiac cachexia. Methods: We identified small molecules that interfere with the MuRF1–titin interaction from a 130 000 compound screen based on Alpha Technology. A subset of nine prioritized compounds were synthesized and administrated during conditions of muscle wasting, that is, to C2C12 muscle cells treated with dexamethasone and to mice treated with monocrotaline to induce cardiac cachexia. Results: The nine selected compounds inhibited MuRF1–titin complexation with IC 50 values <25 μM, of which three were found to also inhibit MuRF1 E3 ligase activity, with one further showing low toxicity on cultured myotubes. This last compound, EMBL chemical core ID#704946, also prevented atrophy in myotubes induced by dexamethasone and attenuated fibre atrophy and contractile dysfunction in mice during cardiac cachexia. Proteomic and western blot analyses showed that stress pathways were attenuated by ID#704946 treatment, including down‐regulation of MuRF1 and normalization of proteins associated with apoptosis (BAX) and protein synthesis (elF2B‐delta). Furthermore, actin ubiquitinylation and proteasome activity was attenuated. Conclusions: We identified a novel compound directed to MuRF1's central myofibrillar protein recognition domain. This compound attenuated in vivo muscle wasting and contractile dysfunction in cardiac cachexia by protecting de novo protein synthesis and by down‐regulating apoptosis and ubiquitin‐proteasome‐dependent proteolysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521 · cited 1×
“glucocorticoids, inflammatory cytokines, reactive oxygen species), while its gene inactivation confers partial resistance to muscle wasting conditions.(7,8,11,12) Therefore, several approaches have attempted to down-regulate MuRF1 activity therapeutically, either directly in vitro via targeted inhibition of MuRF1 by a…”
BackgroundProtein degradation by the ubiquitin-proteasome pathway in normal and disease states
Lecker, S. H., Goldberg, A. L., & Mitch, W. E. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010083 · Cited by 1,234
Muscle wasting in disease: molecular mechanisms and promising therapies
Cohen, S., Nathan, J. A., & Goldberg, A. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4467 · Cited by 1,089
Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome
Sandri, M. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.04.023 · Cited by 689
The E3 Ligase MuRF1 Degrades Myosin Heavy Chain Protein in Dexamethasone-Treated Skeletal Muscle
Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.009 · Cited by 683
Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids
Baehr, L. M., Furlow, J. D., & Bodine, S. C. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.212845 · Cited by 234 · cited 2×
“D5-phenylalanine into MuRF1 KO mice demonstrated an elevated muscle protein translation,(27) while MuRF1 KO mice are protected against a reduction in protein synthesis following DEX treatment.(11) As such, we suggest that MuRF1 mediated”
Background
Cited by
Cancer cachexia: molecular mechanisms and treatment strategies
Setiawan, T., Sari, I. N., Wijaya, Y. T., Julianto, N. M., Muhammad, J. A., Lee, H., Chae, J. H., & Kwon, H. Y. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01454-0 · Cited by 315
Myricanol rescues dexamethasone-induced muscle dysfunction Via a sirtuin 1-dependent mechanism
Shen, S., Liao, Q., Liu, J., Pan, R., Lee, S. M., & Lin, L. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12393 · Cited by 142
“Inhibition of MuRF1 attenuates muscle atrophy.(11) Autophagy is critical to trigger mitochondrial fragmentation in GC-induced muscle atrophy.”
BackgroundSkeletal muscle wasting in chronic heart failure
Suzuki, T., Palus, S., & Springer, J. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12387 · Cited by 134
Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation
Haberecht-Müller, S., Krüger, E., & Fielitz, J. (2021) · Biomolecules · doi:10.3390/biom11091327 · Cited by 108
Adams, V., Bowen, T. S., Werner, S., Barthel, P., Amberger, C., Konzer, A., Graumann, J., Sehr, P., Lewis, J., Provaznik, J., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12448 · Cited by 51
“1% of compound ID#704946, CHF + 704946, n = 12) as recently described.(19) Sham animals that underwent surgery but where the LAD was not ligated served as controls and were fed normal chow (sham, n = 15).”
BackgroundMethodResultInfluentialSelf-citation
Metadata
- Authors
- Bowen, T. S., Adams, V., Werner, S., Fischer, T., Vinke, P., Brogger, M. N., Mangner, N., Linke, A., Sehr, P., Lewis, J., Labeit, D., Gasch, A., & Labeit, S.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2017-09-08
- Volume
- 8
- Issue
- 6
- Pages
- 939-953
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W2751433436
- Cited by
- 107
- References
- 6
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.